2-(2-(2-(2-(4-trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol,
mavatrep,
Mavatrep,
956274-94-5,
JNJ-39439335,
UNII-F197218T99,
F197218T99,
Mavatrep [USAN:INN],
Mavatrep (USAN),
JNJ 39439335,
SCHEMBL1796599,
SCHEMBL1797450,
CHEMBL2364618,
Mavatrep(JNJ-39439335),
Mavatrep; JNJ-39439335,
DTXSID90241905,
BCP23936,
EX-A2266,
BDBM50086717,
ZINC43175494,
AKOS030527038,
CS-4591,
DB12875,
SB17026,
trans-2-(2-(2-(2-(4-Trifluoromethylphenyl)vinyl)-1H-benzimidazol-5-yl)phenyl)propan-2-ol,
BC600772,
HY-16935,
B5930,
J3.561.747G,
D10370,
(E)-2-(2-(2-(4-(trifluoromethyl)styryl)-1H-benzo[d]imidazol-6-yl)phenyl)propan-2-ol,
Benzenemethanol, alpha,alpha-dimethyl-2-(2-((1E)-2-(4-(trifluoromethyl)phenyl)ethenyl)-1H-benzimidazol-6-yl)-,
Mavatrep [USAN],
D0EM4S,
A15778,
2-(2-(2-(4-(trifluoromethyl)styryl)-1H-benzo[d]imidazol-5-yl)phenyl)propan-2-ol,